2024-10-07 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

This report provides a comprehensive analysis of Eli Lilly and Co (LLY) stock, covering its performance, technical indicators, recent earnings, news, and overall outlook.

**1. Performance and Relative Strength**

* **Company Overview:** Eli Lilly and Co is a global pharmaceutical company specializing in the research, development, and manufacturing of pharmaceuticals and biopharmaceutical products.
* **Cumulative Returns:** 
    * **LLY:** 851.72%
    * **VOO (S&P 500):** 133.14%
* **Performance Gap:** LLY has significantly outperformed the S&P 500 with a cumulative return gap of **718.58%**. This gap represents **89.27%** of the historical performance range between LLY and VOO, indicating LLY has consistently outperformed the market benchmark.

**2. Recent Price Movements**

* **Closing Price:** $887.16
* **5-Day Moving Average:** $886.84
* **20-Day Moving Average:** $907.05
* **60-Day Moving Average:** $895.35

The recent price movements suggest a slight downward trend with the closing price below the 5-day, 20-day, and 60-day moving averages.

**3. Technical Indicators**

* **RSI (Relative Strength Index):** 33.45
* **PPO (Percentage Price Oscillator):** -0.46
* **Delta_Previous_Relative_Divergence:** -4.01 (Short-term decline)
* **Expected Return:** 6.72% (Maximum 5-year expected return over S&P 500)

The RSI suggests the stock is currently in oversold territory, while the PPO indicates bearish momentum. The negative Delta_Previous_Relative_Divergence indicates a short-term decline in the stock's relative performance. The expected return suggests potential for future growth, exceeding S&P 500 returns.

**4. Recent Earnings and Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2024-08-08 | 1.96 | 8.31 B$ |

The most recent earnings report (2024-08-08) showed EPS of 3.29, surpassing analysts' estimates of 2.90. This positive earnings beat indicates continued growth and strong performance.  Analysts are optimistic about Eli Lilly's future prospects, citing the success of their diabetes and oncology treatments as key drivers of revenue growth.

**5. News and Recent Issues**

* **Recent Market Outlook for LLY:** The market is currently bullish on LLY, driven by its consistent earnings growth, innovative drug pipeline, and strong market position.
* **Analyst Opinions:** Most analysts rate LLY as a "buy" or "strong buy," with a consensus price target above the current market price.
* **Performance Highlights:** LLY has recently received positive recognition for its strong financial performance, including its growth in revenue and market share.

**6. Overall Analysis**

Eli Lilly and Co (LLY) displays a robust performance history with a strong track record of exceeding the market benchmark. While recent price movements suggest a slight downward trend, technical indicators point to potential oversold conditions and positive future growth. Strong earnings and a favorable market outlook reinforce the bullish sentiment surrounding LLY. 

**7. Key Takeaways:**

* LLY has consistently outperformed the S&P 500, demonstrating its strong market position and long-term potential.
* Recent earnings results showcase continued growth and solid performance, exceeding analysts' expectations.
* Despite current downward price movement, technical indicators suggest potential oversold conditions and potential for future growth.
* Analyst sentiment remains positive, supporting the bullish outlook for LLY stock.

**Disclaimer:** This report provides general information and is not intended as investment advice. Always conduct thorough research and consult with a qualified financial advisor before making investment decisions. 
